BTK and lymphoma: Additionally, a preclinical study identified the synergistic interaction of ricolinostat and ibrutinib the first-in-class BTK (Bruton’s tyrosin kinase) inhibitor in a large panel of lymphoma cell lines and in a xenograft model of lymphoma.